Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review

Table 6 Comparison of the metabolic outcomes in the efruxifermin vs placebo arms

Outcome variables	EFX dose (mg)	No. of study reports	No. of participants with outcome analyzed		Pooled effect size, MD (95%CI)	P value (EFX vs placebo)	I2 (%)	P value (EFX 28 vs 50)
			EFX arm	Placebo arm
Body weight (kg)	28	3	113	124	0.05 (-1.48 to 1.57)	0.95	0	0.13
	50	5	158	144	-1.49 (-2.74 to -0.25)	0.02	0
HbA1c (%)	28	3	113	124	-0.24 (-0.46 to -0.02)	0.03	0	0.24
	50	5	158	144	-0.40 (-0.55 to -0.25)	< 0.00001	0
HOMA-IR	28	3	113	124	-5.70 (-8.21 to -3.19)	< 0.00001	0	0.72
	50	4	135	130	-5.13 (-6.94 to -3.32)	< 0.00001	0
C-peptide (μg/L)	50	2	54	50	-1.16 (-1.59 to -0.73)	< 0.00001	0	NA
Adiponectin (mg/dL)	28	2	55	53	1.95 (0.13 to 3.76)	0.04	76	0.17
	50	3	72	72	3.65 (2.06 to 5.24)	< 0.00001	85
TG (mg/dL)	28	3	111	124	-53.83 (-86.82 to -20.84)	0.001	83	0.68
	50	4	137	134	-63.21 (-92.07 to -34.35)	< 0.0001	82
Non-HDL-C (mg/dL)	28	2	92	103	-16.10 (-29.92 to -2.29)	0.02	68	0.78
	50	3	117	113	-18.40 (-26.99 to -9.81)	< 0.00001	7
LDL-C (mg/dL)	28	3	111	124	-11.10 (-17.84 to -4.35)	0.001	14	0.37
	50	4	137	134	-6.99 (-12.90 to -1.08)	0.02	8
HDL-C (mg/dL)	28	3	111	124	10.77 (7.51 to 14.03)	< 0.00001	46	0.31
	50	4	137	134	12.77 (10.68 to 14.86)	< 0.00001	0
Apo-B (mg/dL)	28	2	56	53	-15.08 (-22.02 to -8.14)	< 0.00001	0	0.39
	50	3	75	73	-11.10 (-17.01 to -5.19)	0.0002	0
Apo-C3 (mg/dL)	28	2	55	63	-2.24 (-4.10 to -0.38)	0.02	69	0.90
	50	2	56	63	-2.44 (-4.89 to 0.01)	0.05	82

Apo-B: Apolipoprotein B; Apo-C3: Apolipoprotein C3; EFX: Efruxifermin; HbA1c: Glycated hemoglobin; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostatic model assessment for insulin resistance; LDL-C: Low-density lipoprotein cholesterol; MD: Mean difference; NA: Not available; TG: Triglycerides.